Online inquiry

IVTScrip™ mRNA-Anti-ITGAV, DI-17E6(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ6649MR)

This product GTTS-WQ6649MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets ITGAV gene. The antibody can be applied in Ovarian Cancer research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 0
Species Humanized
RefSeq NM_001144999.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 3685
UniProt ID P06756
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-ITGAV, DI-17E6(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) (GTTS-WQ6649MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ397MR IVTScrip™ mRNA-Anti-ANGPT2, 2xCon4C(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA 2xCon4C
GTTS-WQ14581MR IVTScrip™ mRNA-Anti-CD38, SAR-650984(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA SAR-650984
GTTS-WQ4749MR IVTScrip™ mRNA-Anti-SOST, BPS-804(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA BPS-804
GTTS-WQ7214MR IVTScrip™ mRNA-Anti-CD19, FMC63 scFv-G4h-28-F9Z-TpERt CAR(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA FMC63 scFv-G4h-28-F9Z-TpERt CAR
GTTS-WQ1604MR IVTScrip™ mRNA-Anti-GDF11, ACE-536(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA ACE-536
GTTS-WQ14166MR IVTScrip™ mRNA-Anti-IL6R, aIL6R88(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA aIL6R88
GTTS-WQ2762MR IVTScrip™ mRNA-Anti-TNFSF11, AMG162(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA AMG162
GTTS-WQ3071MR IVTScrip™ mRNA-Anti-TFPI, Anti-TFPI(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA Anti-TFPI
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW